• Profile
Close

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: A network meta-analysis

OncoTargets and Therapy May 17, 2018

Zhang T, et al. - Researchers determined the optimal sequence, based on the efficacy, for various first-line endocrine monotherapies or combinations for patients with hormone receptor-positive advanced breast cancer. They analyzed data from randomized controlled trials (RCTs) that assessed the effectiveness of the following treatments as a monotherapy or in combination as the first-line treatment: tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, palbociclib, and ribociclib. This analysis included a total of 16 eligible articles (14 RCTs) involving 6,602 patients treated with 10 different first-line endocrine therapies. By providing a longer progression-free survival/time to progression and a more efficacious objective response rate, palbociclib plus letrozole and ribociclib plus letrozole might be the optimal first-line endocrine therapeutic choices for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay